Biodesix, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Scott Hutton
- Full Time Employees
- 334
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 919 West Dillon Road Louisville CO United States of America 80027
- IPO Date
- Oct 28, 2020
- CIK
- 0001439725
- Website
- biodesix.com
- Similar Companies
- Business
- Biodesix, Inc. Biodesix, Inc. (Nasdaq: BDSX) provides blood-based molecular diagnostic testing and development services focused on lung disease and oncology. Founded in 2005 and headquartered in Louisville, Colorado, the company operates primarily in the United States through CLIA-certified laboratories, offering diagnostic solutions that integrate genomics, proteomics, transcriptomics, and radiomics via its proprietary Diagnostic Cortex AI platform. Its core products include the Nodify Lung portfolio with Nodify XL2 and Nodify CDT tests for lung nodule malignancy risk assessment; the IQLung strategy encompassing GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests for advanced non-small cell lung cancer therapy guidance; and biopharmaceutical services such as companion diagnostic development, clinical trial testing, biomarker discovery, and regulatory support. Biodesix serves pulmonologists, thoracic surgeons, oncologists, and biopharma clients, emphasizing non-invasive blood tests to enable personalized treatment decisions and reduce unnecessary procedures. Recent developments include an expanded partnership with Bio-Rad Laboratories in October 2025 to develop and validate Droplet Digital PCR assays, notably the ddPLEX ESR1 mutation detection assay for advanced breast cancer on the QX600 platform; designation as a Thermo Fisher Scientific Center of Excellence for NGS diagnostics in August 2025; a one-for-twenty reverse stock split in September 2025; and a $55 million oversubscribed common stock and private placement financing in April 2024 to support commercial expansion, R&D, and product pipeline advancement.
Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference
Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue?
Wall Street Analysts Think Biodesix (BDSX) Could Surge 31.91%: Read This Before Placing a Bet
Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript
Biodesix Q2 Earnings Call Highlights
Biodesix, Inc. (BDSX) Reports Q2 Loss, Beats Revenue Estimates
Biodesix Announces Second Quarter 2026 Results and Highlights
Biodesix to Participate in Canaccord Genuity's 46th Annual Growth Conference
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
Biodesix, Inc. (NASDAQ:BDSX) Receives $28.33 Consensus PT from Brokerages
Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains?
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
3 Medical Service Industry Stocks Thriving Amid Workforce Challenges
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade
Biodesix to Participate in Upcoming Investor Conferences
Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect?
Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates